Analytical Data
-
Gene name
CD27BP
- Application
-
Alternative Names
SIVA; SIVA1,Apoptosis-Inducing Factor; Apoptosis regulatory protein Siva
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O15304
-
Expression Region
Met1~Thr175
-
Molecular Weight
23kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD27BP, or CD27-binding protein, plays a crucial role in the immune system by modulating T cell activation and proliferation through its interaction with the CD27 receptor. As a member of the tumor necrosis factor (TNF) receptor superfamily, CD27 is an important co-stimulatory molecule that influences T cell responses, making CD27BP a potential target for therapeutic interventions in various diseases, including cancer and autoimmune disorders. Research into CD27BP has gained momentum due to its significant implications in enhancing anti-tumor immunity and improving the efficacy of immunotherapies. Recombinant CD27BP is being studied for its ability to activate T cells and broaden immune responses, thereby providing insights into the development of novel treatments that could optimize existing immunotherapeutic strategies. Understanding the structure-function relationship of CD27BP, along with its signaling pathways, is essential for developing robust therapeutic agents that harness its co-stimulatory effects. This research not only contributes to the fundamental understanding of T cell biology but also opens avenues for clinical applications aimed at augmenting immune responses against malignancies and fine-tuning immune regulation in autoimmune conditions. Thus, exploring the recombinant protein of CD27BP is pivotal for advancing immunotherapy and designing innovative solutions to enhance patient outcomes in various diseases.
